Drug intelligence / Profile preview

HF-CAD

Development stage: Unknown
Lead developer: Hexun Biosciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

HF-CAD is a mesenchymal stem cell (MSC) therapy being developed by Hexun Biosciences for the treatment of heart failure and coronary artery disease (CAD). The program leverages the regenerative and immunomodulatory properties of MSCs to potentially repair damaged myocardial tissue and improve cardiac function in patients suffering from severe coronary artery disease and associated heart failure. Currently in Phase 1 clinical development, the trial is initially enrolling patients with severe conditions to confirm safety and efficacy before expanding the study to the general CAD population.

Other names: Heart Failure with Coronary Artery Disease program心臟疾病併同冠狀動脈疾病

Beyond the preview

Go deeper on HF-CAD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HF-CAD.

Explore the full profile